標(biāo)準(zhǔn)化給藥方案在曲妥珠單抗治療乳腺癌中的應(yīng)用

打開文本圖片集

Application of Standardized Dosing Regimen in the Treatment of Breast Cancer with Trastuzumab

SHI Ya-wen LI Ai-ling WENLi DONGKai （The First People's Hospital of Baiyin， Gansu Province）

Abstract：Objective： To evaluate theclinical efficacy and safety of a standardized dosing regimen in patients with HER2-positive breast cancer treated with Trastuzumab.Methods：This studywasaprospective，randomizedcontrolled trial thatenrolled 80 newlydiagnosed patients with HER2-positiveearly stageormetastatic breast cancer between January 2021 and October 2023. Allparticipants were randomly assigned to two groups： the experimental group （n=40） received a standardized dosing regimenconsisting ofa fixed dose of trastuzumabcombined with a standardized treatment agent； The control group （n=40） ） followed the traditional individualized dosing method. The primary outcome measure wasdisease-freesurvival（DFS），and secondary measuresincluded overallsurvival （OS）andtreatment-related adverseevents （TRAEs）.Results： The DFS in the experimental group was better than that in the control group （P<0.05） ， andthe median DFS in the experimental group was 30 months，compared with 24 months inthe control group.For o s the experimental group alsoshowedabetter trend，althoughthediference didnotreachstatistical significance （P=0.07） 。（剩余4174字）